The company's share price touched a 52-weeks high on Monday on speculation that the global drug major, Pfizer, may buy stake or strike a marketing deal with the company.
"We are growing fast. We are planning to double the manpower to 4,000 from 2,000 at present. Within a very short period we increased the number of employees by 500 to reach 2000," Biocon Chairman and Managing Director Kiran Mazumdar Shaw said.
India Inc on Thursday pitched for lowering income tax burden on common man, increase in capital expenditure, and firm steps to contain food inflation in their nearly two-hour long interaction with finance minister Nirmala Shitharaman ahead of the Union Budget. During pre-Budget consultation with Sitharaman, the industry leaders and associations also urged the government to focus more on infrastructure development with a view to maintaining the economic growth momentum. The industry leaders also laid stress on boosting the MSME (micro, small, and medium enterprises) sector, considered a backbone of the Indian economy and main employment generator.
The Karnataka government on Wednesday put the reservation bill for Kannadigas in private firms on hold amid fierce criticism from business leaders and tech tycoons.
After registering encouraging data from oral insulin trials, Biocon is looking to partner on this with global pharma firms.
Biotechnology major Biocon on Tuesday said it aims to achieve revenues of $1 billion in the next three years.
Indian biotech firm Biocon is developing potential 'blockbuster' drugs for treatment of cancer and diabetes, which could hit the market in two to four years.
Biocon said on Thursday it has granted an exclusive license to Ferozsons Laboratories Ltd for marketing its biotech molecule for treatment of cancer BIOMAb EGFR in Pakistan.
"We will continue to hire people as our growing business demands manpower," CMD Kiran Mazumdar Shaw told reporters while announcing the company's half-yearly results.
The joint venture , Neobiocon, is the company's foray in the region to develop and market bio-pharmaceutical products in areas such as oncology, diabetes, cardiology and anti- obesity.
Profit up due to strong performance of biopharma segment.
Biocon Ltd on Wednesday said it has signed a product licensing agreement with Bentley Pharmaceuticals, Inc, a technology-based specialty pharmaceutical and drug delivery company for Bentley's intranasal spray formulation for administering insulin.
Blaming it on the "ineffective" bureaucracy and "very confused" ruling coalition in Karnataka, Kiran Mazumdar-Shaw, managing director of Biocon Ltd on Friday said infrastructural woes were impeding the growth of Bangalore.
While mostly corporates, including established names and little-known ones, went for the top-denomination bonds, there were also several individuals who bought multiple such bonds.
Biotech major Biocon Ltd's net profit for the quarter ended June 2004 zoomed by 112 per cent at Rs 48.6 crore as compared to Rs 22.9 crore in the first quarter of the previous fiscal.
Biocon was scouting for more strategic alliances and exploring opportunities for outlicensing its biotech drugs under development, as it pitches for a slot among the top three bio-pharmaceutical players across the globe, said Kiran Mazumdar-Shaw, chairman and managing director.
Sources within the Congress, including those who have been members of the teams that drafted its 2019 and 2024 Lok Sabha poll manifestos, said the Karnataka government decision lacked any empirical basis.
Impacted by price pressure and other factors, the country's largest biotech firm, Biocon, on Wednesday reported that its net profit had plummeted 20 per cent to Rs 39 crore
Med Ad News is a global pharmaceutical magazine and is regarded as one of the most respected journals in the segment.
The products, named as 'Erypro Safe' and 'Nufil Safe', have been launched in collaboration with California-based firm Safety Syringes, which makes syringes for vaccines and other medicines. While Erypro Safe is used in the treatment of chronic kidney disease, Nufil Safe is used for cancer treatment. With the new device, patients can be injected with the drug conveniently, without drawing the medicine into a syringe from a vial.
The Biocon chairman said there is a regulatory path for GM crops which aims to establish safety and efficacy over an accepted period and it has been diligently followed by Bt brinjal on the basis of which the Genetic Engineering Approval Committee has given its positive verdict.
Biocon, India's top biotech company, is looking to go in for listing of its stocks overseas in two years time, said its chairman and managing director Kiran Mazumdar-Shaw.
Biocon has managed to heal the wound fast. India's largest biotechnology company, which straddles high-end drug research to generics, bet the wrong way on how the rupee will move against the dollar and paid a big price last year.
India's largest biotechnology company Biocon is planning to tap the potential of biosimilars (generics or copycat versions of biotech drugs going off patent) in the regulated markets of the US and Europe, besides taking Insugen, its own version of insulin, to the global markets in a big way.
Meanwhile, Biocon Ltd has received approvals from the Drug Controller General of India to market Abraxane (nanoparticles based, albumin bound paclitaxel) in India.
Biocon Ltd said on Wednesday it will sell its enzymes venture to Denmark-based Novozymes for $115 million to focus on core bio-pharmaceuticals business.
Biotech major Biocon on Wednesday reported its net profit at Rs 105 crore for the half year ended September 30, 2004, a rise of 75 per cent from Rs 60 crore posted during the corresponding period of last fiscal.
The Bengaluru-headquartered firm had posted a net profit of Rs 84.85 crore (Rs 848.5 million) during the same period of previous fiscal.
At the meeting of the Board of Governors of IIM Bengaluru held on February 11, the chairperson, Mukesh D Ambani, expressed his decision to step down, IIM-B said.
Which entrepreneur would willingly part with her or his hard-earned money for grasping, self-serving politicians? asks Debashis Basu.
While the manufacturing facility would be located in the Jawahar Pharma City, a pharma special economic zone near Visakhapatnam, the R&D facility would be set up in the phase 3 biotech park near Hyderabad.
Leading biotechnology firm Biocon Ltd on Tuesday reported a 22 per cent decline in profit after tax for the half year ended September.
Biotech firm Biocon on Wednesday reported a net profit of Rs 198 crore (Rs 1.98 billion) during 2004-2005, an increase of 42 per cent over Rs 139 crore (Rs 1.39 billion) in the previous fiscal.
Biocon on Thursday reported a 12 per cent decline in consolidated net profit to Rs 174 crore (Rs 1.74 billion) for the year ended March 31, 2006 from Rs 198 crore (Rs 1.98 billion) in FY05.\n
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances